Cita APA (7a ed.)

Xu, C., Zhang, L., Wang, D., Jiang, S., Cao, D., Zhao, Z., . . . Jin, J. (2021). Lipidomics reveals that sustained SREBP-1-dependent lipogenesis is a key mediator of gefitinib-acquired resistance in EGFR-mutant lung cancer. Nature Publishing Group.

Cita Chicago Style (17a ed.)

Xu, Chuncao, Lei Zhang, Daifei Wang, Shiqin Jiang, Di Cao, Zhongxiang Zhao, Min Huang, y Jing Jin. Lipidomics Reveals That Sustained SREBP-1-dependent Lipogenesis Is a Key Mediator of Gefitinib-acquired Resistance in EGFR-mutant Lung Cancer. Nature Publishing Group, 2021.

Cita MLA (8a ed.)

Xu, Chuncao, et al. Lipidomics Reveals That Sustained SREBP-1-dependent Lipogenesis Is a Key Mediator of Gefitinib-acquired Resistance in EGFR-mutant Lung Cancer. Nature Publishing Group, 2021.